FOXO TECHNOLOGIES INC.

FOXO Technologies Inc. (Nasdaq: FOXO) is an insurtech company focused on applying epigenetic biomarker science to life insurance underwriting, and entered public markets in 2022 via a business combination with CF Acquisition Corp VIII, a blank-check company sponsored by Cantor Fitzgerald. The SPAC completed its IPO in 2021, targeting opportunities at the intersection of financial services and biotechnology. FOXO filed a Form 10-Q with the SEC on May 15, 2026, reflecting its continued status as a reporting company following the de-SPAC merger. For detailed filing timelines, sponsor data, and deal analytics on FOXO and the broader SPAC universe, sign up for full access at SpacDesk.